Diadema Partners »

Alkermes shares owned by Diadema Partners

Quarter-by-quarter ownership of Alkermes (ALKS) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Alkermes

Tip: Access up to 7 years of quarterly data

All positions including Alkermes held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alkermes by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-09-30 $2.2M 72k 30.00

More positions owned by Diadema Partners

Jazz Pharmaceuticals Shs Usd (JAZZ)
Soleno Therapeutics (SLNO)
Uniqure Nv SHS Put Option (QURE)
Regeneron Pharmaceuticals (REGN)
Viking Therapeutics (VKTX)
Bristol Myers Squibb (BMY)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
BioMarin Pharmaceutical (BMRN)
Avidity Biosciences Ord (RNA)
Agios Pharmaceuticals Call Option (AGIO)
Ultragenyx Pharmaceutical (RARE)
Incyte Corporation Call Option (INCY)
Intellia Therapeutics Call Option (NTLA)
Vaxcyte (PCVX)
Eli Lilly & Co. Put Option (LLY)

View all positions for Diadema Partners

Top funds holding Alkermes

BlackRock
Vanguard Group
State Street Corporation
Baker Bros. Advisors
Renaissance Technologies
American Century Companies
Geode Capital Management
Jpmorgan Chase & Co
Dimensional Fund Advisors
Commodore Capital
PRIMECAP Management Company
Holocene Advisors
venBio Select Advisor
Nuveen
Charles Schwab Investment Management

View all funds holding Alkermes